Can-Fite BioPharma Ltd.

Contributing Author

Recent Articles by Can-Fite BioPharma Ltd.

Jun-16	Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston CANF GlobeNewswire
May-05	Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis CANF GlobeNewswire